Managed Care
Disease
Management

Hyperphosphatemia

Hyperphosphatemia

Hyperphosphatemia is present in patients with end-stage renal disease and is increasingly important as a clinical entity. Several studies have shown that calcium acetate is more cost-effective than sevelamer as a phosphate binder. Calcium acetate can be used effectively with doses of elemental calcium that meet the K/DOQI guidelines.

Highlights:

  • The CARE Study and Cardiovascular Calcification
  • Controversies in the Management of Hyperphosphatemia in Patients With End-Stage Renal Disease

Meetings

Medical Devices Summit Boston, MA February 19–20, 2015
3rd Annual Summit to Improve Adherence and Enhance Patient Engagement Philadelphia, PA March 9–10, 2015
Value-Added Solutions for Enhanced Customer Experience Philadelphia, PA March 9, 2015